BEMFOLA® CAN POTENTIALLY REDUCE DRUG WASTAGE AND ASSOCIATED COSTS OF INFERTILITY TREATMENT

Foxon G¹, Fox G¹, Mitchell P², Pringle F³, McConnell A⁴, Kendrew H⁵, Craddy P⁶
¹Remap Consulting, Cheshire, United Kingdom; ²Glasgow Centre for Reproductive Medicine, Glasgow, United Kingdom; ³Oxford Fertility Unit, Oxford, United Kingdom; ⁴Ninewells Hospital, Dundee, United Kingdom; ⁵Bath Fertility Centre, Bath, United Kingdom; ⁶Remap Consulting, Bern, Switzerland

Introduction

- Bemfola, an EMA approved biosimilar of Gonal-f, is a recombinant follicle-stimulating hormone (rFSH) used for in-vitro fertilisation (IVF).
- Having demonstrated equivalent efficacy and safety to Gonal-f, Bemfola is approved for identical indications as Gonal-f and as such, is also a viable alternative to urinary derived FSH, Menopur.
- NICE guidance (CG-156) concludes that there is no difference in clinical effectiveness between urinary and recombinant FSH products, and therefore recommends the use of either type of product.²
- However, available products do differ in terms of their delivery device and available strengths; Gonal-f is provided as a multidose pen, Menopur in vials or multidose preparation, and Bemfola as a fixed dose pen.
- The aim of this study was to determine the impact of delivery device on drug wastage and associated cost.

Methods

- A retrospective analysis of Gonal-f and Menopur prescription and usage data from five UK infertility clinics was conducted to identify the level of FSH wastage occurring from IVF cycles.
- Data collected included: number of IVF cycles conducted in the previous 12 months; daily dose; length of treatment; dose adjustment following ultrasound scan; FSH formulation(s) prescribed.
- The drug wastage occurring for conducted cycles was calculated and compared to the potential wastage which would occur if Bemfola were used for the same cycles.
- The wastage cost was then determined using NHS list prices.
- Figures were extrapolated to the annual number of IVF cycles² conducted in the UK to estimate the potential wastage and associated cost to the UK each year.

Results

- A total of 4,724 IVF cycles were incorporated into the analysis.
- If Bemfola were used across all of these cycles instead of the respective gonadotrophin, drug wastage would be reduced by 376,800IU and there would be an associated cost saving of £100,011.
- Extrapolating these data to the annual number of UK IVF cycles results in a potential cost saving of £1,157,579.

Gonal-f wastage versus Bemfola

- Of the 4,078 Gonal-f cycles, overall drug wastage was 650,775IU (5.7% of the total dose prescribed [Figure 1]) equating to 160IU per patient (Figure 2).
- Had Bemfola been used in these patients, the total wastage would have been 424,800IU and the wastage per patient would have been 104IU (Figure 2).

Menopur wastage versus Bemfola

- For the 646 Menopur cycles the wastage was 190,163IU (11.6% of the total dose prescribed [Figure 1]) equating to 294IU per patient (Figure 3).
- Had Bemfola been used in these patients, the wastage would have been reduced to 61IU per patient (Figure 3).

Limitations

- Extrapolation of these results to the number of cycles conducted annually in the UK assumes that Menopur or Gonal-f are used for all IVF cycles and in equal proportions to that seen in the five clinics included in the analysis.
- List prices were used to calculate cost savings when in reality products are offered at discounts. The relative % difference in wastage and therefore cost saving between products will however, remain the same regardless of the price used.

Conclusion

- Using Bemfola as an alternative to Gonal-f or Menopur can potentially reduce drug wastage and associated costs to both patients and the NHS.

Figure 1. % of prescribed dose wasted

- Menopur cycles
- Bemfola
- Gonal-f cycles
- Bemfola
- Gonal-f: 6%
- Menopur: 12%

Figure 2. Gonal-f wastage versus Bemfola

- Comparison of drug wastage (IU)
- Comparison of drug wastage (£)

Figure 3. Menopur wastage versus Bemfola

- Comparison of drug wastage (IU)
- Comparison of drug wastage (£)

References